The US Food and Drug Administration (FDA) has approved Noctiva (desmopressin acetate) nasal spray treatment for adults who wake up at least two times every night due to overproduction of urine, a condition known as nocturnal polyuria.

Renaissance Lakewood markets Noctiva for Serenity Pharmaceuticals.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

FDA centre for drug evaluation and research division of bone, reproductive, and urologic products director Hylton Joffe said: “Today’s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate.

“It is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their healthcare provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.”

Conditions such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate may cause nocturia.

"Today’s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate."

Healthcare providers are required to evaluate each patient for possible causes for this condition, as well as optimise the treatment of underlying conditions prior to considering Noctiva.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Noctiva increases the absorption of water through the kidneys and leads to less urine production.

The efficacy of this treatment was established as part of two 12-week, randomised, placebo-controlled trials conducted in 1,045 patients aged 50 and older.

It should not be used in patients at increased risk of severe hyponatremia or in patients with symptomatic congestive heart failure or uncontrolled hypertension.

Common side effects of Noctiva are nasal discomfort, cold symptoms (nasopharyngitis), nasal congestion, sneezing, high or increased blood pressure, back pain, nosebleeds, bronchitis and dizziness.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact